MLB-301

MLB-301 is a preclinical **monoclonal antibody** reported to target **proprotein convertase subtilisin kexin type 9**, positioning it as a **PCSK9 inhibitor** for treatment of **hypercholesterolemia**. Based on available public references, it appears to have been developed by **Shanghai Bojin Biotechnology** and is described as a biologic lipid-lowering candidate intended to reduce LDL cholesterol by blocking PCSK9-mediated degradation of the LDL receptor. Publicly available information is sparse, and no clear evidence was identified of marketed status, late-stage clinical development, approved brand names, dosage form, or route of administration.